Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 19, 2024, titled "Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)".
Press Release Aug 19 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This launch aims to meet the growing demand for alternatives in the ophthalmic category. The announcement includes a reference to market data indicating significant sales for a comparable product. The company emphasizes its commitment to providing high-quality solutions for customers.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Aug 14 2024
- Press Release Jul 17 2024
- Press Release Jun 12 2024
- Press Release May 24 2024
- Press Release May 21 2024
Later from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Nov 06 2024
- Press Release Nov 14 2024
- Glenmark Pharmaceuticals Limited Press Release Nov 27 2024
- Glenmark Pharmaceuticals Limited Press Release Dec 10 2024
- Glenmark Pharmaceuticals Limited Press Release Dec 16 2024
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals